Lee Rauch is an experienced CEO, Board Member, and Strategy Advisor to public and private companies, with over 35 years of experience. She has deep expertise in M&A, company building, and strategic marketing. She currently serves as a Board Member of Ensysce Biosciences and as a Board Member and Finance Chair for Accent Dance NYC.
Throughout her career, Lee has built successful life science companies from pre-clinical research to advanced clinical development. She restructured and secured over $100 million in financing for the public biotech company MiRagen, later known as Viridian. She has led strategy for emerging companies to increase valuation, including Global Blood Therapeutics, which was later sold to Pfizer, and Onyx, which was acquired by Amgen. Lee also played a key role in the multi-billion-dollar sale of public companies, such as the acquisition of COR Therapeutics by Millennium-Takeda.
Earlier in her career, she led pre-market commercial activities for development-stage therapeutics as Vice President of Strategic Marketing for the Syntex division of Hoffmann-La Roche. She was a founding member of McKinsey & Co.’s International Pharmaceutical Practice and later became a Partner and head of the Pharmaceutical Practice for Mitchell Madison Group.
Lee earned her undergraduate degree in chemistry from Arizona State University and an M.B.A. in finance from the University of Chicago.
